Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.

Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...

Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...

Any significant move would also need support from Evotec’s other major shareholders — Novo Holdings A/S, the parent company of drugmaker Novo Nordisk A/S, as well as Abu Dhabi sovereign fund Mubadala ...

(Reuters) - Europe's STOXX 600 opened lower on Friday, dragged by technology and healthcare stocks, keeping the index on ...

Evotec's other major shareholders are Novo Nordisk parent Novo Holdings and Mubadala Investment. Triton's other investments range from pharmaceutical companies Bormioli Pharma and Clinigen to tank ...

Any significant move would also need support from Evotec's other major shareholders Novo Holdings - the parent company of drugmaker Novo Nordisk - and Abu Dhabi sovereign fund Mubadala Investment ...

EUROPEAN shares slipped on Friday, weighed down by disappointing earnings, concerns about the impact of US President-elect ...

European shares fell on Friday, dragged down by disappointing earnings, concerns about the impact of U.S. President-elect ...

Evotec listed three investors with stakes of 5% or greater in its 2023 annual report. At that time, T. Rowe Price was the ...